JPWO2020021045A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020021045A5
JPWO2020021045A5 JP2021528490A JP2021528490A JPWO2020021045A5 JP WO2020021045 A5 JPWO2020021045 A5 JP WO2020021045A5 JP 2021528490 A JP2021528490 A JP 2021528490A JP 2021528490 A JP2021528490 A JP 2021528490A JP WO2020021045 A5 JPWO2020021045 A5 JP WO2020021045A5
Authority
JP
Japan
Prior art keywords
cells
item
cell population
antibody
items
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021528490A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021532829A5 (https=
JP2021532829A (ja
JP7565271B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/070125 external-priority patent/WO2020021045A2/en
Publication of JP2021532829A publication Critical patent/JP2021532829A/ja
Publication of JP2021532829A5 publication Critical patent/JP2021532829A5/ja
Publication of JPWO2020021045A5 publication Critical patent/JPWO2020021045A5/ja
Priority to JP2024170336A priority Critical patent/JP2025011150A/ja
Application granted granted Critical
Publication of JP7565271B2 publication Critical patent/JP7565271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021528490A 2018-07-26 2019-07-25 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 Active JP7565271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024170336A JP2025011150A (ja) 2018-07-26 2024-09-30 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862703654P 2018-07-26 2018-07-26
US62/703,654 2018-07-26
PCT/EP2019/070125 WO2020021045A2 (en) 2018-07-26 2019-07-25 Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024170336A Division JP2025011150A (ja) 2018-07-26 2024-09-30 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Publications (4)

Publication Number Publication Date
JP2021532829A JP2021532829A (ja) 2021-12-02
JP2021532829A5 JP2021532829A5 (https=) 2022-08-15
JPWO2020021045A5 true JPWO2020021045A5 (https=) 2022-08-15
JP7565271B2 JP7565271B2 (ja) 2024-10-10

Family

ID=67847672

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021528490A Active JP7565271B2 (ja) 2018-07-26 2019-07-25 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法
JP2024170336A Pending JP2025011150A (ja) 2018-07-26 2024-09-30 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024170336A Pending JP2025011150A (ja) 2018-07-26 2024-09-30 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Country Status (8)

Country Link
EP (1) EP3827074A2 (https=)
JP (2) JP7565271B2 (https=)
KR (1) KR102883631B1 (https=)
CN (1) CN112912494B (https=)
AU (1) AU2019311290B2 (https=)
CA (1) CA3106056A1 (https=)
SG (1) SG11202100320QA (https=)
WO (1) WO2020021045A2 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
US10526598B2 (en) 2018-04-24 2020-01-07 Inscripta, Inc. Methods for identifying T-cell receptor antigens
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
AU2019292919A1 (en) 2018-06-30 2021-03-11 Inscripta, Inc. Instruments, modules, and methods for improved detection of edited sequences in live cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
CN113631713A (zh) 2019-03-25 2021-11-09 因思科瑞普特公司 酵母中的同时多重基因组编辑
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020288623A1 (en) 2019-06-06 2022-01-06 Inscripta, Inc. Curing for recursive nucleic acid-guided cell editing
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
EP4069851A4 (en) 2019-12-18 2023-11-22 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
GB202000934D0 (en) * 2020-01-22 2020-03-04 Ucl Business Ltd Engineered immune cells
AU2021213705A1 (en) 2020-01-27 2022-06-16 Inscripta, Inc. Electroporation modules and instrumentation
US20210238535A1 (en) * 2020-02-02 2021-08-05 Inscripta, Inc. Automated production of car-expressing cells
WO2021221766A2 (en) * 2020-02-19 2021-11-04 Barron Annelise E A method of treating cancer by upregulating cathelicidin gene expression and infusing natural killer cells
CN115516085A (zh) * 2020-02-28 2022-12-23 Avm生物技术有限责任公司 淋巴细胞群体以及用于产生所述淋巴细胞群体的方法
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
WO2022060749A1 (en) 2020-09-15 2022-03-24 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
US20230414720A1 (en) * 2020-11-23 2023-12-28 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
IT202000030266A1 (it) * 2020-12-10 2022-06-10 Ospedale Pediatrico Bambino Gesù Car t cells for treating cd19+, cd20+ or cd22+ tumors.
CN112501127B (zh) * 2020-12-21 2023-10-10 广东昭泰细胞生物科技有限公司 一种重编程nk细胞的培养方法
AU2021415461A1 (en) 2021-01-04 2023-08-17 Inscripta, Inc. Mad nucleases
US20240376451A1 (en) 2021-01-07 2024-11-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
GB202115389D0 (en) * 2021-10-26 2021-12-08 XNK Therapeutics AB Methods
CN114107200B (zh) * 2021-11-29 2023-04-21 华东师范大学 一种高纯度CD56+γδT细胞及其制备方法和用途
KR20250079220A (ko) * 2022-10-10 2025-06-04 카이트 파마 인코포레이티드 렌티바이러스 벡터 형질감염을 사용한 신규한 대규모 car-t 면역 세포 제조 방법
CN115651903B (zh) * 2022-11-14 2023-03-17 四川新生命干细胞科技股份有限公司 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用
JP2025541237A (ja) * 2022-12-13 2025-12-18 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド 免疫療法を強化するためのチェックポイントモジュレーター
ES3034332A1 (es) * 2025-05-21 2025-08-14 Univ Madrid Complutense Método de expansión selectiva in vitro y adquisición de fenotipo residente en tejido decélulas T Yo Vo1+ derivadas de sangre periférica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Nk細胞の培養方法及びnk細胞の利用
CN103635573B (zh) * 2011-05-19 2016-05-11 分子医学研究所 包含γδT细胞的淋巴细胞系、其组合物及生产方法
CA3197849A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2016297014B2 (en) * 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF

Similar Documents

Publication Publication Date Title
JPWO2020021045A5 (https=)
CN112912494B (zh) γ-δT细胞和自然杀伤细胞的治疗制剂以及制造和使用方法
US10758625B2 (en) Bispecific antibody capable of being combined with immune cells to enhance tumor killing capability, and preparation method therefor and application thereof
US20210380944A1 (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for making and using them
JP2016520548A5 (https=)
WO2022216514A9 (en) Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells
US20230181644A1 (en) Methods of generating cells
AU2019314452B2 (en) Chimeric antigen receptor therapy T cell expansion kinetics and uses thereof
US12551530B2 (en) Immune cell function
CN119998322A (zh) 基因编辑靶基因以增强自然杀伤细胞功能
Deng et al. Prospects and limitations of NK cell adoptive therapy in clinical applications
JPS5872520A (ja) 継代可能なリンホカイン産生ヒトt細胞融合株及びその取得方法
RU2786210C1 (ru) Биомедицинский клеточный продукт со специфической противоопухолевой активностью, представленный популяциями лимфокин-активированных киллеров и анти-HER2 CAR-γδΤ-ОИЛ и анти-HER2 CAR-T-NK
CN119638851A (zh) 一种用于桥接造血干细胞移植的多靶点嵌合抗原受体及其应用
US20240085403A1 (en) Method for inhibiting adventitious viral infection
HK40055874A (en) Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use
HK40055874B (zh) γ-δ T细胞和自然杀伤细胞的治疗制剂以及制造和使用方法
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法
HK40128442A (zh) 嵌合抗原和t细胞受体及使用的方法
CN118318034A (zh) 用于实体瘤的运输同种异体细胞疗法的工程改造的效应细胞
HK40115765A (zh) 从免疫疗法预测不良事件